Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo

por Gritzapis, A D, Perez, S A, Baxevanis, C N, Papamichail, M
Publicado 2005

Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.

por Baxevanis, C. N., Dedoussis, G. V., Gritzapis, A. D., Stathopoulos, G. P., Papamichail, M.
Publicado 1994

Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells

por Gritzapis, A D, Mamalaki, A, Kretsovali, A, Papamatheakis, J, Belimezi, M, Perez, S A, Baxevanis, C N, Papamichail, M
Publicado 2003

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope

por Sotiriadou, R, Perez, S A, Gritzapis, A D, Sotiropoulou, P A, Echner, H, Heinzel, S, Mamalaki, A, Pawelec, G, Voelter, W, Baxevanis, C N, Papamichail, M
Publicado 2001